Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Frontier Medicines is a pioneer in precision oncology with a unique technology platform and a pipeline of potential best-in-class assets that fit with our oncology strategy |
| We find a space where we think we can do better and more than others with a platform, with the way we deliver cells fresh |
| So the future, I think, with this discovery is very, very good |
| As you can read from the slide, our discontinued operations for the Jyseleca business had a positive contribution to the bottom line of our P&L with a net profit of discontinued operations of EUR216 million |
| We delivered a net profit for the year mainly driven by increased collaboration revenue due to the positive catch-up effect of the revenue recognition from the government |
| So we think that the seven day fresh cells are obviously good for patients and also showing the initial data with a really strong safety profile and efficacy |
| This is extremely promising |
| But we all recognize that this was the breakthrough in autoimmune disease over the last year or two years, and that the progress there is fantastic |
| With the transfer of Jyseleca at Alfasigma, we believe we've secured the best option for patients, our people, and the product |
| And their proprietary chemoproteomics power drug discovery engine with covalent chemistry and machine learning is quite impressive for us to be able to get access to that type of technology for bringing best-in-class, first-in-class, and probably best-in-class drugs in the space of precision medicine |
| Let me conclude by coming back to the strong fundamentals that we put in place to build a global, innovative biotech company and a clear path we have towards value creation |
| We benefit from a very strong balance sheet and we commit to staying disciplined in our use of the cash to focus our investment to maximize value |
| Today, we are a pure-play biotech with strong end-to-end R&D capabilities |
| And the combination of a chemistry platform with these type of targets -- equivalent chemistry platforms with these type of targets could deliver best-in-class medicines and breakthrough products for development |
| And that has yielded a very good clinical result |
| Internally, we also strengthened and continue to strengthen our capabilities in oncology |
| And so far so good |
| In cell therapy, we have an innovative decentralized manufacturing platform for CAR-T, a clinical pipeline and groundbreaking research capabilities |
| What we've been looking for is a best-in-class profile for this molecule |
| We are excited about the company and the potential of a future collaboration |
| We also expanded our scope to bringing in external innovation as we believe that combining internal and external innovation is the best approach to accelerate our pipeline |
| Conclusion, we believe that we have made significant progress in resetting the company to drive value in 2024 and going forward |
| We are strengthening our R&D team capabilities and building a world-class team in Europe and the U.S |
| Also, for ATALANTA, we observed an encouraging safety profile |
| We have a long history and strong legacy of small molecule research and development in immunology and we have now expanded our small molecule efforts into oncology |
| And this is where we think we will look for the best possible modalities to be successful in this area |
| At ASH, in December last year, we presented encouraging safety and efficacy data for our EUPLAGIA program in CLL and Richter's transformation with 5201 in a heavily pretreated patient population |
| Turning to our ATALANTA program in NHL for which we presented Phase I and II data at ASH last year, we observed encouraging efficacy in patients with multiple subtypes of relapse or refractory NHL, again in heavily pretreated patients |
| And so there Frontier complements our activities internally, especially with a new very strong platform |
| Meanwhile, we have significantly increased our capabilities and expertise to support our growth in our key therapeutic areas of interest, immunology and oncology as we continue to build on our R&D organization, including in the U.S |
| Statement |
|---|
| So I think that's where catching up with those who are in front of us, from a development perspective, is the first challenge |
| So do you see there being other opportunities in autoimmune diseases that you'd consider moving forward in with development programs? Maybe categories with fewer ongoing studies or less crowded? It seems like there's a big disadvantage to being late order of entry in this space, and maybe from a regulatory development perspective, maybe that gets more complicated |
| For strategic reasons, we decided to discontinue the development of our CD19 CAR-T in refractory SLE |
| I would also like to point out the reduction in OpEx, down 8% year-over-year due to a decrease in R&D costs and SG&A |
| Paul Stoffels Sorry, Sebastian, can you get closer to your phone? Because very difficult to understand |
| Other companies can use their approved products in that space, and that is competitively very difficult to catch up with |
| Because these forward-looking statements involve risks and uncertainties, Galapagos' actual results may differ materially from the results expressed or implied in these statements |
| It looked like maybe the timelines were pushed back just a little bit |
Please consider a small donation if you think this website provides you with relevant information